Drug intelligence / Profile preview

docetaxel + taselisib

Development stage: Unknown
Lead developer: Genentech
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Docetaxel + taselisib is a combination therapy consisting of docetaxel, a taxane chemotherapy agent, and taselisib (GDC-0032), a selective PI3K inhibitor. Taselisib works by blocking the PI3K pathway, particularly targeting PIK3CA-mutant tumors, while docetaxel is a cytotoxic agent that disrupts microtubule function. This combination was investigated for the treatment of locally advanced or metastatic breast cancer and non-small cell lung cancer (NSCLC).

Targets

TUBB (Tubulin (alpha and beta subunits))PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)BCL-2 (BCL-2 family)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on docetaxel + taselisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on docetaxel + taselisib.

Explore the full profile